BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22219001)

  • 1. The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer.
    Laitman Y; Herskovitz L; Golan T; Kaufman B; Paluch SS; Friedman E
    Fam Cancer; 2012 Jun; 11(2):243-7. PubMed ID: 22219001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population.
    Foulkes WD; Thiffault I; Gruber SB; Horwitz M; Hamel N; Lee C; Shia J; Markowitz A; Figer A; Friedman E; Farber D; Greenwood CM; Bonner JD; Nafa K; Walsh T; Marcus V; Tomsho L; Gebert J; Macrae FA; Gaff CL; Paillerets BB; Gregersen PK; Weitzel JN; Gordon PH; MacNamara E; King MC; Hampel H; De La Chapelle A; Boyd J; Offit K; Rennert G; Chong G; Ellis NA
    Am J Hum Genet; 2002 Dec; 71(6):1395-412. PubMed ID: 12454801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A636P is associated with early-onset colon cancer in Ashkenazi Jews.
    Guillem JG; Rapaport BS; Kirchhoff T; Kolachana P; Nafa K; Glogowski E; Finch R; Huang H; Foulkes WD; Markowitz A; Ellis NA; Offit K
    J Am Coll Surg; 2003 Feb; 196(2):222-5. PubMed ID: 12595050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-amplicon MSH2 A636P mutation testing in Ashkenazi Jewish patients with colorectal cancer: role in presurgical management.
    Guillem JG; Glogowski E; Moore HG; Nafa K; Markowitz AJ; Shia J; Offit K; Ellis NA
    Ann Surg; 2007 Apr; 245(4):560-5. PubMed ID: 17414604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome.
    Raskin L; Schwenter F; Freytsis M; Tischkowitz M; Wong N; Chong G; Narod SA; Levine DA; Bogomolniy F; Aronson M; Thibodeau SN; Hunt KS; Rennert G; Gallinger S; Gruber SB; Foulkes WD
    Clin Genet; 2011 Jun; 79(6):512-22. PubMed ID: 21155762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rate of the recurrent MSH6 mutations in Ashkenazi Jewish breast cancer patients.
    Bernstein-Molho R; Laitman Y; Schayek H; Iomdin S; Friedman E
    Cancer Causes Control; 2019 Jan; 30(1):97-101. PubMed ID: 30498870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC.
    Goldberg Y; Porat RM; Kedar I; Shochat C; Galinsky D; Hamburger T; Hubert A; Strul H; Kariiv R; Ben-Avi L; Savion M; Pikarsky E; Abeliovich D; Bercovich D; Lerer I; Peretz T
    Fam Cancer; 2010 Jun; 9(2):141-50. PubMed ID: 19851887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lynch Syndrome in high risk Ashkenazi Jews in Israel.
    Goldberg Y; Kedar I; Kariiv R; Halpern N; Plesser M; Hubert A; Kaduri L; Sagi M; Lerer I; Abeliovich D; Hamburger T; Nissan A; Goldshmidt H; Solar I; Geva R; Strul H; Rosner G; Baris H; Levi Z; Peretz T
    Fam Cancer; 2014 Mar; 13(1):65-73. PubMed ID: 23990280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homozygosity of MSH2 c.1906G-->C germline mutation is associated with childhood colon cancer, astrocytoma and signs of Neurofibromatosis type I.
    Toledano H; Goldberg Y; Kedar-Barnes I; Baris H; Porat RM; Shochat C; Bercovich D; Pikarsky E; Lerer I; Yaniv I; Abeliovich D; Peretz T
    Fam Cancer; 2009; 8(3):187-94. PubMed ID: 19101824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A636P testing in Ashkenazi Jews.
    Guillem JG; Moore HG; Palmer C; Glogowski E; Finch R; Nafa K; Markowitz AJ; Offit K; Ellis NA
    Fam Cancer; 2004; 3(3-4):223-7. PubMed ID: 15516845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel MSH2 germline mutation in a Druze HNPCC family.
    Zidan J; Niessen RC; Laitman Y; Rozeveld D; Hofstra RM; Friedman E
    Fam Cancer; 2008; 7(2):135-9. PubMed ID: 17661183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium.
    Plaschke J; Engel C; Krüger S; Holinski-Feder E; Pagenstecher C; Mangold E; Moeslein G; Schulmann K; Gebert J; von Knebel Doeberitz M; Rüschoff J; Loeffler M; Schackert HK
    J Clin Oncol; 2004 Nov; 22(22):4486-94. PubMed ID: 15483016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
    Ponti G; Manfredini M; Tomasi A; Pellacani G
    Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MLH1 promoter germline-methylation in selected probands of Chinese hereditary non-polyposis colorectal cancer families.
    Zhou HH; Yan SY; Zhou XY; Du X; Zhang TM; Cai X; Lu YM; Cai SJ; Shi DR
    World J Gastroenterol; 2008 Dec; 14(48):7329-34. PubMed ID: 19109866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gynecologic malignancies in Ashkenazi families with the MSH2 A636P founder mutation.
    Lavie O; Gruber SB; Lejbkowicz F; Dishon S; Rennert G
    Am J Obstet Gynecol; 2008 Aug; 199(2):148.e1-3. PubMed ID: 18674656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
    Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
    Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HNPCC associated MSH2*1906G-->C founder mutation probably originated between 1440 CE and 1715 CE in the Ashkenazi Jewish population.
    Sun S; Greenwood CM; Thiffault I; Hamel N; Chong G; Foulkes WD
    J Med Genet; 2005 Oct; 42(10):766-8. PubMed ID: 16199548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation.
    Mukherjee B; Rennert G; Ahn J; Dishon S; Lejbkowicz F; Rennert HS; Shiovitz S; Moreno V; Gruber SB
    Gastroenterology; 2011 Jun; 140(7):1919-26. PubMed ID: 21419771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity.
    Baris HN; Barnes-Kedar I; Toledano H; Halpern M; Hershkovitz D; Lossos A; Lerer I; Peretz T; Kariv R; Cohen S; Half EE; Magal N; Drasinover V; Wimmer K; Goldberg Y; Bercovich D; Levi Z
    Pediatr Blood Cancer; 2016 Mar; 63(3):418-27. PubMed ID: 26544533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.